Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

OBJECTIVES: Primary Objective To evaluate the overall response rate Secondary Objectives To assess the safety and tolerability To assess the duration of response To assess the progression free survival and overall survival STATISTICAL DESIGN: This trial will use a single stage design to differentiate a \>/= 25% response rate from a \</= 5% rate. If observed data is consistent with the alternative response rate of 25%, imatinib would be deemed clinically interesting and worthy of a larger phase II study.